Shop in your local currency and language

Choose another country or region to see specific content for your location and shop online.

United Kingdom

Development of an α-synuclein knockdown peptide and evaluation of its efficacy in Parkinson’s disease models

作者:王玉田,董志芳等
发表年份:2021年
发表期刊:Communications Biology
作者单位:重庆医科大学附属儿童医院,加拿大英属哥伦比亚大学等
地区:重庆省


文章摘要

Convincing evidence supports the premise that reducing α-synuclein levels may be an effective therapy for Parkinson’s disease (PD); however, there has been lack of a clinically applicable α-synuclein reducing therapeutic strategy. This study was undertaken to develop a blood-brain barrier and plasma membrane-permeable α-synuclein knockdown peptide, Tatβsyn-degron, that may have therapeutic potential. The peptide effectively reduced the level of α-synuclein via proteasomal degradation both in cell cultures and in animals. Tat-βsyn-degron decreased α-synuclein aggregates and microglial activation in an α-synuclein preformed fibril model of spreading synucleinopathy in transgenic mice overexpressing human A53T α-synuclein. Moreover, Tat-βsyn-degron reduced α-synuclein levels and significantly decreased the parkinsonian toxin-induced neuronal damage and motor impairment in a mouse toxicity model of PD. These results show the promising efficacy of Tat-βsyn-degron in two different animal models of PD and suggest its potential use as an effective PD therapeutic that directly targets the disease-causing process.

实验方法

使用机型:Biacore 3000
实验类型:亲和力/动力学表征
样品类型:配体:human α-synuclein蛋白;分析物:peptides
实验芯片:C系列CM5芯片
配体固定方式:氨基偶联
运行缓冲液:10mM HEPES, 150mM NaCl, 3mM EDTA, and 0.005% surfactant P20, pH 7.4

产品信息

类别 货号 产品名称 规格
主机 Biacore 3000
芯片 BR100399 C系列CM5芯片 1片
芯片 BR100012 C系列CM5芯片 3片
芯片 29149604 C系列CM5芯片 10片
试剂盒 BR100050 氨基偶联试剂盒
运行缓冲液 BR100669 HBS-EP+ (10×) 1 × 1000 mL
运行缓冲液 BR100826 HBS-EP+ (10×) 4 × 50 mL

Reference

Jin JW, Fan X, Del Cid-Pellitero E, Liu XX, Zhou L, Dai C, Gibbs E, He W, Li H, Wu X, Hill A, Leavitt BR, Cashman N, Liu L, Lu J, Durcan TM, Dong Z, Fon EA, Wang YT. Development of an α-synuclein knockdown peptide and evaluation of its efficacy in Parkinson's disease models. Commun Biol. 2021 Feb 19;4(1):232. doi: 10.1038/s42003-021-01746-6. PMID: 33608634; PMCID: PMC7895943.